COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I REGNREGN LY-CoVLY RemdesivirRMD
HCQ study #152 of 230
10/12 Late treatment study
Annie et al., Pharmacotherapy, doi:10.1002/phar.2467 (Peer Reviewed)
Hydroxychloroquine in hospitalized COVID‐19 patients: Real world experience assessing mortality
Source   PDF   Share   Tweet
Retrospective database analysis with PSM not including COVID-19 severity, finding mortality OR 0.95 [0.62-1.46] for HCQ, and 1.24 [0.70-2.22] for HCQ+AZ. Confounding by indication likely.

Annie et al., 10/12/2020, retrospective, database analysis, USA, North America, peer-reviewed, 5 authors.
risk of death, 4.3% lower, RR 0.96, p = 0.83, treatment 48 of 367 (13.1%), control 50 of 367 (13.6%), odds ratio converted to relative risk.
risk of death, 20.5% higher, RR 1.21, p = 0.46, treatment 29 of 199 (14.6%), control 24 of 199 (12.1%), odds ratio converted to relative risk.
Details of all 230 studies    Meta analysis
Please submit corrections, updates, or comments.